SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Zydus Cadila receives USFDA nod for Irbesartan Tablets

01 Oct 2012 Evaluate

Zydus Cadila, an innovative global pharmaceutical company, has received US Food Drug and Administrator (USFDA) approval for Irbesartan Tablets USP 75 mg, 150 mg and 300 mg. Irbesartan is a drug used in the treatment of hypertension. As per NDC, the estimated sales in 2011 for Irbesartan Tablets was $489 million.

With this approval, the group now has 72 approvals and has so far filed 150 ANDAs since the commencement of filing process in FY 2003-04.

Flagship company of Zydus Cadila Group, it focuses on various areas, such as formulations (human and veterinary), new drug discovery, novel drug delivery, pharmaceutical ingredients, analytical research, phytochemistry, biotechnology, plant tissue culture, etc.

Zydus Lifesciences Share Price

939.20 3.20 (0.34%)
16-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1693.15
Dr. Reddys Lab 1221.25
Cipla 1230.75
Zydus Lifesciences 939.20
Lupin 2326.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×